** Shares of drugmaker Insmed INSM.O rise 24.9% to $88.28 premarket
** Co says its treprostinil palmitil inhalation powder (TPIP) met the main goal in a mid-stage trial by reducing blood flow resistance in the lungs by 35% when compared to placebo
** The drug was tested in patients with Pulmonary Arterial Hypertension (PAH), a rare disease caused by a constriction of arteries in the lungs, leading to high blood pressure
** Co says the treatment is administered once-daily in a capsule-based inhalation device
** INSM says it plans to initiate a late-stage trial for the drug in early 2026
** Up to last close, stock up 2.4% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.